QCDX
Company Snapshot
Company Overview
QCDx LLC is developing and commercializing the RareScope platform for detecting CTCs at an early stage, when cancer can be cured.
The RareScope Fluorescence Light Sheet Microscope provides sensitive detection of intact and live CTCs from multiple phenotypes without the need for enrichment.
RarePicker micromanipulation isolates intake/live cells for single cell analysis, including genomic, transcriptomic, epigenetic, and proteomic.
The RareVivo specimen chamber enables ex vivo imaging of cells while perfused with media in a 3D continuous culture. This allows for evaluation of cancer drugs on CTCs and white blood cells before they are administered to a patient.
QCDx’s platform differs from other CTC liquid biopsies, which use enrichment for CTC detection in patient blood. No system offers ex vivo cell imaging as does the QCDx system.
QCDX In News
Company's Business Segments
- Biotechnology Research : This segment dedicated to providing solutions for Detecting, Profiling Rare Cells in the Blood Circulation.
Applications/End User Industries
- Biotechnology
- Healthcare
- Clinics
- Pharmaceutical
- Research Organizations
- Heterogeneity
- Tumor Cells
- Immunofluorescent
- Rare Cell Profiling
